Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model

Jun Ichi Yokoe, Norio Iwasaki, Shunji Haruta, Keitaro Kadono, Ken Ichi Ogawara, Kazutaka Higaki, Toshikiro Kimura

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The gastrointestinal-transit-absorption (GITA) model is useful for the analysis and the prediction of the absorption behavior of drugs orally administered as solutions. In the present study, we tried to predict the plasma concentration-time profile of a colon-targeted prodrug, salicylazosulfanilic acid (SASA), and its parent drug, 5-aminosalicylic acid (5-ASA) which is regenerated after dosing. Prediction of plasma concentration-time profiles for SASA and 5-ASA was performed based on the GITA model using parameters describing GI-transit kinetics, the absorption in each GI segment, and the regeneration of 5-ASA in cecum. Plasma concentration-time profiles of both SASA and 5-ASA after oral administration of SASA were predicted very well by introducing a factor for the first-pass elimination of 5-ASA into the GITA model. The simulation study using the parameters obtained in the present study showed that about 94.7% of SASA reaches the cecum, where 5-ASA is regenerated very rapidly and 76.0% of 5-ASA is absorbed. Furthermore, the bioavailability of 5-ASA was estimated to be 0.330 because of the first-pass elimination through both cecum and liver. In conclusion, the absorption behaviors of a prodrug and its regenerated parent drug can be predicted very well and be clarified successfully using the GITA model.

Original languageEnglish
Pages (from-to)305-313
Number of pages9
JournalJournal of Controlled Release
Volume86
Issue number2-3
DOIs
Publication statusPublished - Jan 17 2003

Fingerprint

Mesalamine
Prodrugs
Colon
Gastrointestinal Transit
Cecum
Acids
Pharmaceutical Preparations
Biological Availability
Oral Administration
Regeneration
Gastrointestinal Absorption
Liver

Keywords

  • GITA model
  • Oral absorption
  • Parent drug
  • Prediction
  • Prodrug

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model. / Yokoe, Jun Ichi; Iwasaki, Norio; Haruta, Shunji; Kadono, Keitaro; Ogawara, Ken Ichi; Higaki, Kazutaka; Kimura, Toshikiro.

In: Journal of Controlled Release, Vol. 86, No. 2-3, 17.01.2003, p. 305-313.

Research output: Contribution to journalArticle

Yokoe, Jun Ichi ; Iwasaki, Norio ; Haruta, Shunji ; Kadono, Keitaro ; Ogawara, Ken Ichi ; Higaki, Kazutaka ; Kimura, Toshikiro. / Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model. In: Journal of Controlled Release. 2003 ; Vol. 86, No. 2-3. pp. 305-313.
@article{88647d78103f48f38878906f22a15b5c,
title = "Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model",
abstract = "The gastrointestinal-transit-absorption (GITA) model is useful for the analysis and the prediction of the absorption behavior of drugs orally administered as solutions. In the present study, we tried to predict the plasma concentration-time profile of a colon-targeted prodrug, salicylazosulfanilic acid (SASA), and its parent drug, 5-aminosalicylic acid (5-ASA) which is regenerated after dosing. Prediction of plasma concentration-time profiles for SASA and 5-ASA was performed based on the GITA model using parameters describing GI-transit kinetics, the absorption in each GI segment, and the regeneration of 5-ASA in cecum. Plasma concentration-time profiles of both SASA and 5-ASA after oral administration of SASA were predicted very well by introducing a factor for the first-pass elimination of 5-ASA into the GITA model. The simulation study using the parameters obtained in the present study showed that about 94.7{\%} of SASA reaches the cecum, where 5-ASA is regenerated very rapidly and 76.0{\%} of 5-ASA is absorbed. Furthermore, the bioavailability of 5-ASA was estimated to be 0.330 because of the first-pass elimination through both cecum and liver. In conclusion, the absorption behaviors of a prodrug and its regenerated parent drug can be predicted very well and be clarified successfully using the GITA model.",
keywords = "GITA model, Oral absorption, Parent drug, Prediction, Prodrug",
author = "Yokoe, {Jun Ichi} and Norio Iwasaki and Shunji Haruta and Keitaro Kadono and Ogawara, {Ken Ichi} and Kazutaka Higaki and Toshikiro Kimura",
year = "2003",
month = "1",
day = "17",
doi = "10.1016/S0168-3659(02)00424-8",
language = "English",
volume = "86",
pages = "305--313",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model

AU - Yokoe, Jun Ichi

AU - Iwasaki, Norio

AU - Haruta, Shunji

AU - Kadono, Keitaro

AU - Ogawara, Ken Ichi

AU - Higaki, Kazutaka

AU - Kimura, Toshikiro

PY - 2003/1/17

Y1 - 2003/1/17

N2 - The gastrointestinal-transit-absorption (GITA) model is useful for the analysis and the prediction of the absorption behavior of drugs orally administered as solutions. In the present study, we tried to predict the plasma concentration-time profile of a colon-targeted prodrug, salicylazosulfanilic acid (SASA), and its parent drug, 5-aminosalicylic acid (5-ASA) which is regenerated after dosing. Prediction of plasma concentration-time profiles for SASA and 5-ASA was performed based on the GITA model using parameters describing GI-transit kinetics, the absorption in each GI segment, and the regeneration of 5-ASA in cecum. Plasma concentration-time profiles of both SASA and 5-ASA after oral administration of SASA were predicted very well by introducing a factor for the first-pass elimination of 5-ASA into the GITA model. The simulation study using the parameters obtained in the present study showed that about 94.7% of SASA reaches the cecum, where 5-ASA is regenerated very rapidly and 76.0% of 5-ASA is absorbed. Furthermore, the bioavailability of 5-ASA was estimated to be 0.330 because of the first-pass elimination through both cecum and liver. In conclusion, the absorption behaviors of a prodrug and its regenerated parent drug can be predicted very well and be clarified successfully using the GITA model.

AB - The gastrointestinal-transit-absorption (GITA) model is useful for the analysis and the prediction of the absorption behavior of drugs orally administered as solutions. In the present study, we tried to predict the plasma concentration-time profile of a colon-targeted prodrug, salicylazosulfanilic acid (SASA), and its parent drug, 5-aminosalicylic acid (5-ASA) which is regenerated after dosing. Prediction of plasma concentration-time profiles for SASA and 5-ASA was performed based on the GITA model using parameters describing GI-transit kinetics, the absorption in each GI segment, and the regeneration of 5-ASA in cecum. Plasma concentration-time profiles of both SASA and 5-ASA after oral administration of SASA were predicted very well by introducing a factor for the first-pass elimination of 5-ASA into the GITA model. The simulation study using the parameters obtained in the present study showed that about 94.7% of SASA reaches the cecum, where 5-ASA is regenerated very rapidly and 76.0% of 5-ASA is absorbed. Furthermore, the bioavailability of 5-ASA was estimated to be 0.330 because of the first-pass elimination through both cecum and liver. In conclusion, the absorption behaviors of a prodrug and its regenerated parent drug can be predicted very well and be clarified successfully using the GITA model.

KW - GITA model

KW - Oral absorption

KW - Parent drug

KW - Prediction

KW - Prodrug

UR - http://www.scopus.com/inward/record.url?scp=0037449482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037449482&partnerID=8YFLogxK

U2 - 10.1016/S0168-3659(02)00424-8

DO - 10.1016/S0168-3659(02)00424-8

M3 - Article

C2 - 12526826

AN - SCOPUS:0037449482

VL - 86

SP - 305

EP - 313

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2-3

ER -